Zentalis Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-12-01
- Employees
- 168
- Market Cap
- $216.8M
- Website
- http://www.zentalis.com
- Introduction
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation for Cyclin E1 Positive Ovarian Cancer
FDA granted Fast Track Designation to azenosertib for Cyclin E1 positive ovarian cancer patients, highlighting its potential to address unmet medical needs. Zentalis Pharmaceuticals to share clinical data and regulatory updates on January 29, 2025. Research supports azenosertib's efficacy in Cyclin E1/CDK2 activated tumors.
Zentalis Pharmaceuticals, Inc. Announces Azenosertib Fast Track Designation for Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals received FDA Fast Track Designation for azenosertib to treat platinum-resistant ovarian cancer. A webcast on January 29, 2025, will present study data, including Phase 2 DENALI and Phase 1b ZN-c3-001 results, and updates on azenosertib's development and regulatory status.
Zentalis Gets FDA Fast-Track Designation for Azenosertib
Zentalis Pharmaceuticals received FDA fast-track designation for azenosertib, targeting Cyclin E1-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer patients, aiming to address high unmet medical needs and poor outcomes associated with chemotherapy resistance.
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Webcast
Zentalis Pharmaceuticals will host a webcast on January 29, 2025, to present azenosertib study data, including Phase 2 DENALI and Phase 1b ZN-c3-001 trial results, and updates on azenosertib's development and regulatory path. Azenosertib, a WEE1 inhibitor, shows promise in treating various cancers by enabling cell cycle progression despite DNA damage.
Zentalis' Cancer Drug Azenosertib Receives FDA Fast Track Status for Ovarian Cancer Treatment
Zentalis Pharmaceuticals received FDA Fast Track Designation for azenosertib, targeting Cyclin E1 positive ovarian cancer patients, highlighting its potential to address unmet medical needs. A corporate event on January 29, 2025, will update on azenosertib's clinical data and regulatory path. Research in npj Precision Oncology supports azenosertib's sensitivity in Cyclin E1/CDK2 activated models.
Zentalis Pharmaceuticals Announces Azenosertib Fast Track
FDA grants Fast Track Designation to azenosertib for Cyclin E1 positive ovarian cancer patients, highlighting its potential to address unmet medical needs. Zentalis to present azenosertib clinical data and regulatory updates on January 29, 2025. Research in npj Precision Oncology supports Cyclin E1/CDK2 activation as a predictor of azenosertib sensitivity.
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition
Azenosertib, synthesized by Zentalis Pharmaceuticals, was tested on various human cancer cell lines for cell viability and proliferation. Techniques included cell proliferation assays, Jess Simple Western analysis, generation of stable cell lines, siRNA knockdown, DNA fiber assays, immunofluorescence, immunohistochemistry, high-content imaging, and in vivo studies. Statistical analysis used GraphPad Prism, with clinical trials conducted under U.S. ethical guidelines.
Related Clinical Trials:
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Zentalis Pharmaceuticals granted 45,000 non-qualified stock options to two new employees under the 2022 Inducement Plan, with a $3.00 exercise price, vesting over four years. The company focuses on developing cancer therapeutics, including azenosertib, a WEE1 inhibitor for solid tumors.
Zentalis Pharmaceuticals Announces Key Management Appointments
Zentalis Pharmaceuticals focuses on developing azenosertib, a WEE1 inhibitor for advanced solid tumors, showing promise in clinical trials. The company explores genomic instability in tumors and advances research on protein degraders, aiming for azenosertib to be first-in-class and best-in-class.
Geographic Disparities in Gynecologic Oncology Clinical Trial Availability in the US
Study finds states with higher economic vulnerability and minoritized populations have fewer gynecological cancer trials per 100,000 persons, highlighting the need for efforts to address these disparities.
© Copyright 2025. All Rights Reserved by MedPath